We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Pain Tolerance Determined by Single Amino Acid Replacement

By Biotechdaily staff writers
Posted on 05 Mar 2003
Researchers into the genetic basis of pain tolerance found that a mutation in the gene that codes for the enzyme catechol-O-methyl transferase (COMT) determined how well healthy volunteers were able to tolerate levels of experimentally induced pain. More...
Their findings were published in the February 21, 2003, issue of Science.

COMT, an enzyme linked to the metabolism of the neurotransmitter chemicals dopamine and noradrenaline, has two alleles that differ by one amino acid, either valine or methionine, at position 158. Investigators from the University of Michigan (Ann Arbor, USA) studied 29 participants, 15 men and 14 women, aged 20 to 30 years. The volunteers received injections of salt-water into their jaw muscles. The injections were meant to simulate temporomandibular joint pain disorder, which is a useful human model of sustained pain, and physical and emotional stress.

Positron-emission tomography (PET) brain-imaging scanning was used in combination with a radioactive tracer that illuminated mu-opioid receptors and indicated how the receptors become activated in the brain in response to a sustained pain stressor. The study showed that participants with two copies of the methionine form of the COMT gene had a much more pronounced response to pain than those who carried two copies of the valine form of the gene. Those with one copy of each form of COMT had a pain tolerance somewhere between the responses of the other two groups. At the molecular level, the valine form of the enzyme promoted a more effective dopamine-metabolizing system.

"Participants who had two copies of the valine form withstood quite a bit more pain than others in the study, while at the same time reporting that they felt less pain and fewer pain-related negative emotions,” explained first author Dr. Jon-Kar Zubieta, a neuroscientist at the University of Michigan. "This common genetic variation appears to influence individuals' pain response quite noticeably, both in their neurochemical response and in their affective responses and internal affective states. These data also emphasize the need to understand how genes influence our behavior by examining the intermediary brain pathways and mechanisms regulated by those genes.”




Related Links:
University of Michigan

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.